Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Tibet Rhodiola Pharmaceutical Holding Co's Liquidation Value for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co Total Current Assets Related Terms
Tibet Rhodiola Pharmaceutical Holding Co Total Current Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co Total Current Assets Chart
Tibet Rhodiola Pharmaceutical Holding Co Annual Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of ¥4,796 Mil mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Total Current Assets of ¥4,796 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Tibet Rhodiola Pharmaceutical Holding Co and its competitors.
Is Tibet Rhodiola Pharmaceutical Holding Co's Total Current Assets too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Total Current Assets is ¥4,796 Mil. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Total Current Assets compare to ZTS and UTHR?
Tibet Rhodiola Pharmaceutical Holding Co's Total Current Assets of ¥4,796 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Drug Manufacturers company?
A good Total Current Assets depends on the Drug Manufacturers industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Tibet Rhodiola Pharmaceutical Holding Co and its competitors. Tibet Rhodiola Pharmaceutical Holding Co's current Total Current Assets is ¥4,796 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥40.60 — trading 0.2% above its estimated fair value. The current Total Current Assets is ¥4,796 Mil. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Total Current Assets is ¥4,796 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be overvalued.
The current stock price of ¥40.60 is trading 0.2% above its estimated GF Value™ of ¥40.53.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
Total Current Assets: ¥4,796 Mil
GF Value™: ¥40.53 vs. price of ¥40.60 (0.2% above fair value)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co Business Description
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score
Get the complete analysis for SHSE:600211
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
